Pages that link to "Item:Q3079132"
From MaRDI portal
The following pages link to Continual Reassessment Method for Ordered Groups (Q3079132):
Displaying 14 items.
- Adaptive isotonic estimation of the minimum effective and peak doses in the presence of covariates (Q419309) (← links)
- Incorporating a patient dichotomous characteristic in cancer phase I clinical trials using escalation with overdose control (Q454783) (← links)
- Continual reassessment and related dose-finding designs (Q903292) (← links)
- A Bayesian adaptive design in cancer phase I trials using dose combinations in the presence of a baseline covariate (Q1733138) (← links)
- Individualized dosing for multiple ordered groups of patients (Q2320813) (← links)
- Bayesian data augmentation dose finding with continual reassessment method and delayed toxicity (Q2441853) (← links)
- Adaptive clinical trial designs for phase I cancer studies (Q2452091) (← links)
- Theoretical study of the continual reassessment method (Q2492919) (← links)
- A Hierarchical Bayesian Design for Phase I Trials of Novel Combinations of Cancer Therapeutic Agents (Q3064270) (← links)
- Patient‐Specific Dose Finding Based on Bivariate Outcomes and Covariates (Q3549405) (← links)
- Risk-Group-Specific Dose Finding Based on an Average Toxicity Score (Q3576932) (← links)
- Patient-specific dose finding in phase I clinical trials (Q5036370) (← links)
- Two‐Dimensional Dose Finding in Discrete Dose Space (Q5715373) (← links)
- A Bayesian adaptive phase I/II clinical trial design with late‐onset competing risk outcomes (Q6076490) (← links)
